Pharmicell Co.,Ltd.
Pharmicell, founded in 1968 and listed in 1988, operates biomedical and biochemical divisions in stem cell therapeutics and fine chemicals.
Price
Change
Market cap
Business overview
Source: DART corporate disclosurePharmicell was founded in 1968 and listed on the KOSPI in 1988 as a biopharmaceutical company operating a Biomedical division and a Biochemical division. The Biomedical division develops the stem cell therapy Hearticellgram-AMI, runs an adult stem cell storage business, and produces cosmetics containing stem cell culture extract, while the Biochemical division, built around 아이디비켐(주) which was acquired in 2012 and merged in 2013, manufactures electronic materials, pharmaceutical intermediates such as Nucleoside and mPEG, and eco-friendly phosphorus-based flame retardants. For the 58th fiscal term, revenue totaled 114,062, with 111,538 from the Biochemical division and 2,524 from the Biomedical division.
Products & technology
- Hearticellgram-AMIStem cell therapy
- Adult stem cell storage serviceAdult stem cell storage
- Cosmetics containing stem cell culture extractCosmetics
- Electronic materialsElectronic materials with low dielectric constant and loss
- Pharmaceutical intermediates (Nucleoside, mPEG)Pharmaceutical intermediates
- Phosphorus-based flame retardantEco-friendly phosphorus flame retardant for textile and electronic materials
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2021
- MFDS drugHearticellgram-AMI2021-08-26Drug · Prescription · Approval202106185
Clinical trials
data.go.kr13 MFDS clinical trial authorisations · 2012–2024 (Phase 1 6 · Phase 2 4 · Phase 3 2 · Phase 4 1)
- Phase 2셀그램이디(Cellgram-ED)2024-08-02
4 trial sites
- Phase 1셀그램-씨케이디 (Cellgram-CKD)2021-07-27
1 trial site
- Phase 3셀그램-엘씨 (Cellgram-LC)2020-12-02
15 trial sites
- Phase 1셀그램-디씨-피씨 (Cellgram-DC-PC)2020-06-25
1 trial site
- Phase 1셀그램-디씨 (Cellgram-DC)2020-06-25
1 trial site
- Phase 2셀그램이디(Cellgram-ED)2020-06-11
4 trial sites
- Phase 1셀그램이디(Cellgram-ED)2019-01-14
1 trial site
- Phase 2셀그램-엘씨 (Cellgram-LC)2015-12-16
10 trial sites
- Phase 1셀그램이디(Cellgram-ED)2014-09-26
1 trial site
- Phase 1Cellgram-CLI2014-09-22
1 trial site
- Phase 2셀그램-엘씨 (Cellgram-LC)2012-11-06
12 trial sites
- Phase 3MSC2(하티셀그램-에이엠아이)2012-07-09
5 trial sites
Show 1 more
- Phase 4MSC2(하티셀그램-에이엠아이)2012-03-23
4 trial sites
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition